While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...

Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs’ Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update on the Local Coverage Determinations (“LCDs”) regarding “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.”   These new LCDs were ...

MiMedx (MDXG) closed the last trading session at $6.93, gaining 20.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $12.33 indicates a 77.9% upside potential.The average comprises six short-term price targets ranging from a low of $11 to a high of $14, with a standard deviation of $1.03. While the lowest estimate indicates an increase of 58.7% from the current price level, the mo ...

Financial Data and Key Metrics Changes - For Q3 2024, net sales increased by $2 million or 3% year-over-year to $84 million, aligning with previous expectations [10][27] - Gross profit margin remained stable at 82%, with adjusted EBITDA at $18 million or 22% of net sales, reflecting a $600,000 increase from the prior year [11][36] - Cash balance rose by $20 million to $89 million, transitioning from a net interest expense of $1.7 million in Q3 2023 to net interest income of approximately $300,000 in Q3 2024, indicating a nearly $2 million positive cash swing [12][36] Business Line Data and Key Metrics Changes - Wound sales reached $55 million, growing 8% year-over-year, while surgical sales were $29 million, down 5% as reported; however, excluding discontinued products, surgical sales increased by 5% [28] - AMNIOEFFECT grew by 29% year-over-year in the surgical market, and EPIEFFECT showed significant strength in the private office [15][28] - HELIOGEN, the new xenograft product, is in its initial market release phase, contributing modestly to sales [15][28] Market Data and Key Metrics Changes - Net sales in the private office grew 11% to approximately $25 million, driven by strong EPIEFFECT sales despite challenges in the reimbursement environment [29] - Hospital channel sales declined 3% to $46 million, attributed to employee churn and reduced AXIOFILL sales [30] - International sales grew about 9% to nearly $12.5 million, marking the highest level of international net sales in years [32] Company Strategy and Development Direction - The company focuses on three strategic priorities: innovation and diversification of the product portfolio, expanding the surgical market footprint, and enhancing customer intimacy [15][23] - The introduction of HELIOGEN is expected to open new market opportunities and contribute significantly in 2025 [18][76] - The company is committed to generating real-world evidence and scientific research to support the use of its products in various surgical procedures [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, anticipating that current reimbursement headwinds will dissipate in the coming year [9][45] - The company is confident that corrective actions regarding Medicare reimbursement are on the horizon, which could positively impact future sales [7][44] - Full-year revenue growth guidance has been raised from mid to high single digits, with expectations for adjusted EBITDA margins above 20% [45][46] Other Important Information - The company has successfully maintained a healthy operating margin despite challenges in the reimbursement environment [11][36] - The recent New York Times article highlighted the benefits of placental tissue, showcasing the company's products indirectly [14][21] Q&A Session Summary Question: Reimbursement dynamics and confidence in upcoming changes - Management noted increased confidence in reimbursement corrections based on recent interactions with CMS and congressional staff, indicating urgency for change [50][52] Question: Impact of discontinued products on surgical sales - The impact of discontinued dental products and AXIOFILL was quantified, showing a potential 10-point swing in surgical sales performance [53][58] Question: Expectations for HELIOGEN's contribution in 2025 - Management indicated that HELIOGEN is expected to fill some of the gap left by AXIOFILL, though it may not fully replace it [62] Question: SG&A expense outlook - SG&A expenses are expected to remain consistent in the near term, with no significant cuts anticipated [63] Question: R&D initiatives and CMS feedback - Management confirmed ongoing RCT initiatives and that studies are still deemed necessary by CMS, with some spending expected to ramp up in the coming quarters [70][71] Question: Margin outlook and drivers - Management expressed confidence in margin accretion with scale, expecting adjusted EBITDA margins to remain above 20% [72][74] Question: HELIOGEN launch experience - Early feedback on HELIOGEN has been positive, with expectations that it will open new doors in the market [76][88]

MiMedx (MDXG) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 40%. A quarter ago, it was expected that this developer of biomaterials made from sterilized human amniotic membrane would post earnings of $0.08 per share when it actually produced earnings of $0.08, delivering no surprise ...

Exhibit 99.1 MIMEDX Announces Third Quarter 2024 Operating and Financial Results Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, Respectively Third Quarter Adjusted EBITDA was $18 Million, or 22% of Net Sales Raises 2024 Net Sales Growth Expectations to the High Single-Digits Management to Host Conference Call Today, October 30, 2024, at 4:30 PM ET MARIETTA, Ga., October 30, 2024 — MiMedx Group, Inc. (Nasda ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Florida 26-2 ...

Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, Respectively Third Quarter Adjusted EBITDA was $18 Million, or 22% of Net Sales Raises 2024 Net Sales Growth Expectations to the High Single-Digits Management to Host Conference Call Today, October 30, 2024, at 4:30 PM ET MARIETTA, Ga., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company"), today announced operating an ...

Earnings Announcement - The company will report its operating and financial results for the third quarter ended September 30, 2024 after the market close on Wednesday, October 30, 2024 [1] - The senior management team will host a webcast and conference call to review the results beginning at 4:30 p m Eastern Time on the same day [1] - The conference call can be accessed via webcast or by dialing 877-407-6184 for U S investors and 201-389-0877 for international investors with Conference ID 13748866 [1] - A replay of the webcast will be available for approximately 30 days on the company's website at www mimedx com following the conclusion of the event [1] Company Overview - The company is a pioneer and leader in helping humans heal, with over a decade of experience in assisting clinicians with chronic and hard-to-heal wounds [2] - It is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare [2] - The company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life [2] Contact Information - For investor relations inquiries, contact Matt Notarianni at 470-304-7291 or mnotarianni@mimedx com [3]

MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today highlighted the publication of a feature article on placental allografts for patients with hard-to-heal, acute and chronic wounds, which was published in today's New York Times: "Her Face Was Unrecognizable After an Explosion. A Placenta Restored It." The author underscored the benefits of placental allografts for a variety of wound care and surgical procedures and brought attention to the la ...